BSEBeryl Drugs LtdMediumNeutral
Announced Wed, 1 Apr · 16:44 IST

OUTCOME OF BOARD MEETING

Director Flagged GovernanceManagement Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.6%1-day move
₹18.98
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6+18.9+31.7+36.9+28.1+31.9+15.9+20.6+13.2+20.8
Up moveDown movePending
AI summary

The board meeting held on April 1, 2026 approved convening an Extra Ordinary General Meeting (EOGM) to regularize the appointment of Mr. Shailendra Pathak as Whole Time Director and Mrs. Neha Sarda as Independent Director. The meeting also approved material related party transactions with M/s. Aminova Infusions P. Ltd., where Mr. Shailendra Pathak holds 50% equity and serves as director — this self-interested transaction is being presented for shareholder approval. Additionally, Abhay Bhandari & Associates was appointed as Internal Auditor for FY 2026-2027, and Mrs. Dipika Kataria was named scrutinizer for the EOGM voting process.

Likely market impact

The related party transaction with Aminova Infusions, where the appointee director holds a significant stake, raises governance concerns and will require shareholder approval at the EOGM. Investors should scrutinize the terms of both the director appointment and the related party dealings.